Analysis of the association between KIN17 expression and the clinical features/prognosis of epithelial ovarian cancer, and the effects of KIN17 in SKOV3 cells

Chen,Junyu; Xia,Yang; Peng,Yuanqing; Wu,Shan; Liu,Wei; Zhang,Haoxian; Wang,Tian; Yang,Zhaoyun; Zhao,Shuhua; Zhao,Lijing

doi:10.3892/ol.2021.12736

Analysis of the association between KIN17 expression and the clinical features/prognosis of epithelial ovarian cancer, and the effects of KIN17 in SKOV3 cells

Authors:
- Junyu Chen
- Yang Xia
- Yuanqing Peng
- Shan Wu
- Wei Liu
- Haoxian Zhang
- Tian Wang
- Zhaoyun Yang
- Shuhua Zhao
- Lijing Zhao
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, The Second Hospital of Jilin University, Changchun, Jilin 130022, P.R. China, Department of Pathology, The Second Hospital of Jilin University, Changchun, Jilin 130022, P.R. China, Research Center for Circular Economy and Pollution Prevention, Jilin Academy of Environmental Sciences, Changchun, Jilin 130021, P.R. China, Department of Pharmacy, Xuchang Municipal Hospital, Xuchang, Henan 461000, P.R. China, Department of Recovery, Nursing School of Jilin University, Changchun, Jilin 130012, P.R. China
Published online on: April 15, 2021 https://doi.org/10.3892/ol.2021.12736
Article Number: 475
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DNA double‑strand breaks (DSBs) are an important mechanism of chemotherapy in epithelial ovarian cancer (EOC). Kin17 DNA and RNA binding protein (KIN17) serves a crucial role in DSB repair. In the present study, the association between KIN17 and EOC, and the effects of KIN17 on EOC cells in vitro were evaluated. A bioinformatics method was used to determine the mRNA expression levels of KIN17 in EOC and its association with EOC prognosis including overall survival (OS) and progression free survival (PFS) time. Western blotting and immunohistochemical staining were used to evaluate the expression levels of KIN17 in EOC samples. Kaplan‑Meier and Cox regression analyses were utilized to analyze risk factors for the OS of patients with EOC. A Cell Counting Kit‑8 assay was performed to explore the roles of KIN17 in SKOV3 cells. Both the transcription and expression of KIN17 were upregulated in EOC tissues. Furthermore, the OS of patients with EOC with high mRNA expression levels of KIN17 was shorter than that of patients with EOC with low expression levels. High KIN17 expression was an independent risk factor for EOC prognosis. Furthermore, KIN17 knockdown inhibited the proliferation of SKOV3 cells, enhanced the sensitivity of the cells to cisplatin and inhibited the migration ability of the cells. These results suggested that KIN17 may act as an ideal candidate for therapy and as a prognostic biomarker of EOC, although the underlying mechanisms require further exploration.

View Figures

View References

1	Lheureux S, Gourley C, Vergote I and Oza AM: Epithelial ovarian cancer. Lancet. 393:1240–1253. 2019. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
3	Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014. View Article : Google Scholar : PubMed/NCBI
4	Griffiths RW, Zee YK, Evans S, Mitchell CL, Kumaran GC, Welch RS, Jayson GC, Clamp AR and Hasan J: Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int J Gynecol Cancer. 21:58–65. 2011. View Article : Google Scholar : PubMed/NCBI
5	Boussios S, Karihtala P, Moschetta M, Karathanasi A, Sadauskaite A, Rassy E and Pavlidis N: Combined strategies with poly (ADP-Ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: A literature review. Diagnostics (Basel). 9:872019. View Article : Google Scholar : PubMed/NCBI
6	Luvero D, Milani A and Ledermann JA: Treatment options in recurrent ovarian cancer: Latest evidence and clinical potential. Ther Adv Med Oncol. 6:229–239. 2014. View Article : Google Scholar : PubMed/NCBI
7	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
8	Wang QE, Milum K, Han C, Huang YW, Wani G, Thomale J and Wani AA: Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells. Mol Cancer. 10:242011. View Article : Google Scholar : PubMed/NCBI
9	Borst P, Rottenberg S and Jonkers J: How do real tumors become resistant to cisplatin? Cell Cycle. 7:1353–1359. 2008. View Article : Google Scholar : PubMed/NCBI
10	Norouzi-Barough L, Sarookhani MR, Sharifi M, Moghbelinejad S, Jangjoo S and Salehi R: Molecular mechanisms of drug resistance in ovarian cancer. J Cell Physiol. 233:4546–4562. 2018. View Article : Google Scholar : PubMed/NCBI
11	Burdova K, Storchova R, Palek M and Macurek L: WIP1 promotes homologous recombination and modulates sensitivity to PARP inhibitors. Cells. 8:12582019. View Article : Google Scholar : PubMed/NCBI
12	Lord CJ and Ashworth A: The DNA damage response and cancer therapy. Nature. 481:287–294. 2012. View Article : Google Scholar : PubMed/NCBI
13	Jiang QG, Xiong CF and Lv YX: Kin17 facilitates thyroid cancer cell proliferation, migration, and invasion by activating p38 MAPK signaling pathway. Mol Cell Biochem. 476:727–739. 2021. View Article : Google Scholar : PubMed/NCBI
14	The Cancer Genome Atlas Research Network, . Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
15	Denis SFB, Miccoli L, Despras E, Frobert Y, Creminon C and Angulo JF: Ionizing radiation triggers chromatin-bound kin17 complex formation in human cells. J Biol Chem. 277:19156–19165. 2002. View Article : Google Scholar : PubMed/NCBI
16	Zeng T, Gao H, Yu P, He H, Ouyang X, Deng L and Zhang Y: Up-regulation of kin17 is essential for proliferation of breast cancer. PLoS One. 6:e253432011. View Article : Google Scholar : PubMed/NCBI
17	Zhang Y, Gao H, Gao X, Huang S, Wu K, Yu X, Yuan K and Zeng T: Elevated expression of Kin17 in cervical cancer and its association with cancer cell proliferation and invasion. Int J Gynecol Cancer. 27:628–633. 2017. View Article : Google Scholar : PubMed/NCBI
18	Kou WZ, Xu SL, Wang Y, Wang LW, Wang L, Chai XY and Hua QL: Expression of Kin17 promotes the proliferation of hepatocellular carcinoma cells in vitro and in vivo. Oncol Lett. 8:1190–1194. 2014. View Article : Google Scholar : PubMed/NCBI
19	Zhang Y, Huang S, Gao H, Wu K, Ouyang X, Zhu Z, Yu X and Zeng T: Upregulation of KIN17 is associated with non-small cell lung cancer invasiveness. Oncol Lett. 13:2274–2280. 2017. View Article : Google Scholar : PubMed/NCBI
20	Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, et al: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 10:3291–3300. 2004. View Article : Google Scholar : PubMed/NCBI
21	Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, Simms L, Locandro B, Fereday S, Traficante N, et al: Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res. 6:1678–1690. 2008. View Article : Google Scholar : PubMed/NCBI
22	Györffy B, Surowiak P, Kiesslich O, Denkert C, Schäfer R, Dietel M and Lage H: Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 118:1699–1712. 2006. View Article : Google Scholar
23	Gyorffy B, Lánczky A and Szállási Z: Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012. View Article : Google Scholar : PubMed/NCBI
24	Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U: Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 95 (Suppl 1):S161–S192. 2006. View Article : Google Scholar
25	Kong D, Chen J, Sun X, Lin Y, Du Y, Huang D, Cheng H, He P, Yang L, Wu S, et al: GRIM-19 over-expression represses the proliferation and invasion of orthotopically implanted hepatocarcinoma tumors associated with downregulation of Stat3 signaling. Biosci Trends. 13:342–350. 2019. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Kannouche P, Mauffrey P, Pinon-Lataillade G, Mattei MG, Sarasin A, Daya-Grosjean L and Angulo JF: Molecular cloning and characterization of the human KIN17 cDNA encoding a component of the UVC response that is conserved among metazoans. Carcinogenesis. 21:1701–1710. 2000. View Article : Google Scholar : PubMed/NCBI
28	Despras E, Miccoli L, Créminon C, Rouillard D, Angulo JF and Biard DS: Depletion of KIN17, a human DNA replication protein, increases the radiosensitivity of RKO cells. Radiat Res. 159:748–758. 2003. View Article : Google Scholar : PubMed/NCBI
29	Ovarian cancer. Nat Rev Dis Primers. 2:160622016. View Article : Google Scholar : PubMed/NCBI
30	Haynes B, Saadat N, Myung B and Shekhar MP: Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance. Mutat Res Rev Mutat Res. 763:258–266. 2015. View Article : Google Scholar : PubMed/NCBI
31	Prat J: New insights into ovarian cancer pathology. Ann Oncol. 23 (Suppl 10):x111–x117. 2012. View Article : Google Scholar : PubMed/NCBI
32	Doufekas K and Olaitan A: Clinical epidemiology of epithelial ovarian cancer in the UK. Int J Womens Health. 6:537–545. 2014.PubMed/NCBI
33	Chen H, Lisby M and Symington LS: RPA coordinates DNA end resection and prevents formation of DNA hairpins. Mol Cell. 50:589–600. 2013. View Article : Google Scholar : PubMed/NCBI
34	Xue Z, Zhu X and Teng Y: Long non-coding RNA CASC2 inhibits progression and predicts favorable prognosis in epithelial ovarian cancer. Mol Med Rep. 18:5173–5181. 2018.PubMed/NCBI